---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-23-000082"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2023-10-31T23:59:59+00:00"
generated_at: "2026-06-09T04:57:27.923475+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics reports preclinical CTIM-76 data showing tumor regressions; IND on track for Q1 2024

## Summary
- CTIM-76 induced dose-proportional tumor regressions and was well tolerated in xenograft models.
- CTIM-76 showed ten-fold higher potency than AMG-794 in in vitro cytotoxicity and cytokine activation assays.
- CTIM-76 retained activity across low to high CLDN6 expression, unlike TORL-1-23 which depended on high expression.
- IND filing for CTIM-76 planned for late Q1 2024.
- Approximately 70,000 US patients with CLDN6-positive metastatic solid tumors have no approved targeted treatment.

## SEC filing metadata
- accession: 0001842952-23-000082
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2023-10-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295223000082/0001842952-23-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295223000082/cntx-20231031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-23-000082
- JSON: https://secwatch.observer/filing/0001842952-23-000082.json
- Plain text: https://secwatch.observer/filing/0001842952-23-000082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.